Pharma's Lp(a) Bet Faces Key Data
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Large pharmaceutical companies are betting that targeting a particle called lipoprotein(a) will be the next big advance in cardiovascular medicine
- Key clinical data on the lipoprotein(a)-targeting drug class is approaching, which will determine how well the approach actually works
Why it matters: Multiple large pharma companies have collectively wagered on lipoprotein(a) as the next cardiovascular advance, so the imminent clinical readouts will validate or undermine a significant sector-wide bet on an entirely new drug class.
Ask SkimNews
